National Asset Management Inc. lifted its position in shares of Becton Dickinson and Co (NYSE:BDX) by 8.7% during the 1st quarter, HoldingsChannel reports. The firm owned 1,456 shares of the medical instruments supplier’s stock after acquiring an additional 117 shares during the period. National Asset Management Inc.’s holdings in Becton Dickinson and were worth $364,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. Oregon Public Employees Retirement Fund boosted its position in shares of Becton Dickinson and by 22,485.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 6,545,502 shares in the last quarter. Ronna Sue Cohen boosted its position in shares of Becton Dickinson and by 24,129.0% during the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock valued at $5,734,000 after purchasing an additional 5,710,365 shares in the last quarter. Norges Bank bought a new stake in shares of Becton Dickinson and during the fourth quarter valued at approximately $515,703,000. Mackenzie Financial Corp boosted its position in shares of Becton Dickinson and by 27.7% during the fourth quarter. Mackenzie Financial Corp now owns 1,943,752 shares of the medical instruments supplier’s stock valued at $437,966,000 after purchasing an additional 421,825 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Becton Dickinson and by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock valued at $1,103,526,000 after purchasing an additional 416,459 shares in the last quarter. Institutional investors own 84.03% of the company’s stock.
In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,340 shares of Becton Dickinson and stock in a transaction on Monday, February 25th. The stock was sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the completion of the transaction, the chief executive officer now owns 227,250 shares in the company, valued at $56,903,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Samrat S. Khichi sold 16,085 shares of Becton Dickinson and stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $234.68, for a total value of $3,774,827.80. Following the transaction, the executive vice president now owns 12,608 shares of the company’s stock, valued at approximately $2,958,845.44. The disclosure for this sale can be found here. Insiders have sold 47,469 shares of company stock valued at $11,675,851 in the last quarter. 0.12% of the stock is owned by company insiders.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.57 by $0.02. The business had revenue of $4.20 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The firm’s quarterly revenue was down .6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.65 earnings per share. As a group, research analysts anticipate that Becton Dickinson and Co will post 11.7 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Friday, June 7th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date is Thursday, June 6th. Becton Dickinson and’s payout ratio is 27.97%.
Several equities research analysts recently weighed in on the company. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. Wells Fargo & Co dropped their price target on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating on the stock in a research report on Monday, May 13th. Barclays upgraded Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price target on the stock in a research report on Monday, May 13th. BMO Capital Markets dropped their price target on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating on the stock in a research report on Friday, May 10th. Finally, Morgan Stanley dropped their price target on Becton Dickinson and from $255.00 to $250.00 and set an “equal weight” rating on the stock in a research report on Friday, May 10th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $255.31.
TRADEMARK VIOLATION WARNING: This story was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://sportsperspectives.com/2019/05/26/national-asset-management-inc-grows-position-in-becton-dickinson-and-co-bdx.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Momentum Investing
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.